Back to Journals » OncoTargets and Therapy » Call For Papers

OncoTargets and Therapy

ISSN: 1178-6930

The following Article Collections/ Thematic Series are currently open for submissions:

Cancer Immunotherapy: Harnessing the Immune System for Cancer Treatments

Dove Medical Press is pleased to invite you to submit your research to the upcoming Article Collection “Cancer Immunotherapy: Harnessing the Immune System for Cancer Treatments” organized by Guest Advisor Dr. Anna Maria Di Giacomo in OncoTargets and Therapy.

In the last decade, harnessing the immune system with immune checkpoint blockades has achieved remarkable results in solid tumors of different histotypes, enabling durable responses and long-term survival. Despite these unprecedented results, primary or acquired resistance can limit its efficacy; therefore a deeper understanding of the underlying mechanism of resistance is crucial for the identification of novel therapeutic strategies in several clinical settings (e.g. adjuvant, neo-adjuvant setting, rare tumors, etc.). In this exciting scenario, to untangle the threads of immunotherapy, research needs to answer some key questions, ranging from the mechanistic exploration causing lack of response, to the identification of biomarkers, but also the development of novel immunotherapeutic modalities and their clinical applications.

In this regard, we are seeking original research, and review article submissions on the following topics:
• Immune-checkpoint blockade for cancer treatment: from biology to clinical results
• Therapeutic combinations of immune-modulating antibodies
• Immunotherapies for brain metastases and brain primary tumors
• Immunotherapies for ocular melanoma
• Immunotherapies for rare tumors
• Immunotherapy in adjuvant and neoadjuvant settings
• Mechanisms of immune escape and potential strategies to overcome resistance
• Epigenetic immune remodeling to improve the efficacy of cancer immunotherapies
• Harnessing T-cell metabolism to improve anti-tumor responses
• Microbioma and immune-checkpoint blockade therapy
• Beyond immune-checkpoint(s): new targets for cancer immunotherapy
• Imaging challenges of immunotherapy
• Biomarkers of immune response and toxicity in immunotherapy
• Radiomics and deep learning approach in cancer immunotherapy

All manuscripts submitted to this Article Collection will undergo desk assessment and peer-review as part of our standard editorial process. Please review the journal Aims and Scope and author submission instructions prior to submitting a manuscript.

The deadline for submissions is 31 December 2023.

Please submit your manuscript on our website, quoting the promo code ZDDYW to indicate that your submission is for consideration in this Article Collection.

View all papers in this article collection

Understand and target the complexity of the tumor milieu

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Understand and target the complexity of the tumor milieu" in OncoTargets and Therapy.

The process of tumor initiation and progression is influenced by genetic/epigenetic alterations in tumor cells and the rearrangement of the tumor microenvironment (TME) through complex signaling networks. The TME consists of various components, including tumor cells, stromal fibroblasts, endothelial cells, immune cells, and extracellular matrix (ECM) components. Crosstalk between tumor cells and these non-malignant cells in the TME plays a critical role in promoting tumorigenesis, metastasis, and drug resistance.

Interactions within the TME involve cytokines, chemokines, growth factors, and other mediators, as well as novel mechanisms such as circulating tumor cells (CTCs), exosomes, cell-free DNA (cfDNA), and apoptotic bodies that contribute to horizontal gene transfer between tumor and normal cells. Understanding these interactions is essential to understanding tumor growth and metastasis. Targeting the TME offers potential opportunities for cancer treatment and personalized therapy.

This Article Collection seeks research and review articles that focus on the molecular interactions between cancer cells and TME components, the link between tumor heterogeneity and metabolic plasticity, and related strategies that can bridge the gap between preclinical and clinical research.

The deadline for submissions is 31 August 2024. Please review the journal’s aims and scope and author submission instructions prior to submitting a manuscript.

Please submit your manuscript on our website, quoting the promo code SCXVO to indicate that your submission is for consideration in this Article Collection.

Guest advisors

Yong Teng, Emory University and Georgia Tech

[email protected]

Dr. Teng is an Associate Professor in the Department of Hematology and Medical Oncology at Emory University and an Adjunct Associate Professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University. He is the inaugural recipient of the Winship Cancer Institute Wally Award and a member of the BME Program and BDCI at Emory University. Dr. Teng's primary research interests are in tumor microenvironment, tumor metabolism and metastasis, with a focus on molecular determinants and paradigm-shifting treatment regimens.

Nabil F. Saba, Emory University

[email protected]

Dr. Saba is Professor and Vice Chair of the Department of Hematology and Medical Oncology. He holds the Lynne and Howard Halpern Chair in Head and Neck Cancer Research and serves as Co-Director of the Head and Neck Cancer Multidisciplinary Program at the Winship Cancer Institute of Emory University. Dr. Saba is a recognized expert in immunotherapy for head and neck cancer and leads numerous translational research efforts focused on targeting the tumor microenvironment.


View all papers in this article collection

Call For Papers

Editor-in-Chief: Professor Gaetano Romano

To see where OncoTargets and Therapy is indexed online view the Journal Metrics.

What is the advantage to you of publishing in OncoTargets and Therapy?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although OncoTargets and Therapy receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. OncoTargets and Therapy has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
OncoTargets and Therapy is indexed on PubMed Central (title abbreviation: Onco Targets Ther). All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Professor Gaetano Romano
OncoTargets and Therapy

Email: Editor-in-Chief